+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod



Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod



Thrombosis Research 104(6): 433-438



Ancrod is a purified fraction of venom from the Malayan pit viper, Calloselasma rhodostoma, currently under investigation for treatment of ischemic stroke. The therapeutic effect is ascribed to a lowering of plasma fibrinogen. Thirty-two healthy volunteers received subcutaneous ancrod at doses of 1.0, 1.5 and 2.0 IU/kg body weight or placebo. Blood samples were drawn before the injection and at various time points until 96 h after the injection. Ancrod leads to the formation of desAA-fibrin, which serves as cofactor in tissue plasminogen activator activity (tPA)-induced plasminogen activation. Unchanged concentrations of prothrombin fragment F1.2 and thrombin-antithrombin complex (TAT) indicate that fibrin formation occurs independent of thrombin. Plasmin generation is independent of an increase in tPA activity or changes in plasminogen activator inhibitor-1 (PAI-1) concentration in plasma. Subcutaneous injection of ancrod leads to a generalized fibrino(geno)lytic response caused solely by providing tPA with soluble fibrin as its cofactor in plasminogen activation. Maximal plasmin activity is present 12 h after subcutaneous injection.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011160029

Download citation: RISBibTeXText

DOI: 10.1016/s0049-3848(01)00391-7


Related references

Plasminogen activation without changes in tPA and PAI-1 in response to subcutaneous administration of ancrod. Thrombosis Research 104(6): 433-438, 2002

Enhancement of plasminogen activation by tissue type plasminogen activator in the presence of ancrod and fibrinogen. Thrombosis & Haemostasis 58(1): 436, 1987

Potentiation of plasminogen activation by ancrod and reptilase. Federation Proceedings 32(3 Part 1): 427, 1973

SDS polyacrylamide gel characterization of serum FDP produced in response to ancrod and streptokinase/plasminogen infusion in man. British Journal of Haematology 36(1): 137-148, 1977

Sodium dodecyl sulfate poly acrylamide gel characterization of serum fibrin fibrinogen degradation products produced in response to ancrod and strepto kinase plasminogen infusions in man. British Journal of Haematology 36(1): 137-148, 1977

Plasminogen activation in diabetes mellitus. Kinetics of plasmin formation with tissue plasminogen activator and plasminogen from individual diabetic donors and with in vitro glucosylated plasminogen. Enzyme 40(2-3): 149-157, 1988

Subcutaneous ancrod in prevention of deep-vein thrombosis. Lancet 1(8106): 51-52, 1979

Prevention of deep vein thrombosis by subcutaneous ancrod. Scottish Medical Journal 23(4): 329-330, 1978

Different effects of intraperitoneal or subcutaneous administration of H2-antagonists on pancreatic response to chronic administration of caerulein in rats. Digestion 41(3): 129-135, 1988

Subcutaneous ancrod after operation for fractured hip--a dose-ranging and feasibility study. Thrombosis and Haemostasis 40(1): 134-143, 1978

Subcutaneous ancrod in prevention of deep vein thrombosis after hip replacement surgery. Thrombosis Research 25(1-2): 23-31, 1982

Plasminogen activator inhibitor: a regulator of ancrod-induced fibrin deposition in rabbits. Blood 69(3): 798-803, 1987

Plasminogen activation in unstable angina is associated with an acute phase response but not with activation of the hemostatic system. Journal of the American College of Cardiology 27(2 Suppl. A): 307A-308A, 1996

Relative importance of thrombin compared with plasmin mediated platelet activation in response to plasminogen activation with streptokinase. Circulation 84(4): 1552-1560, 1991

Subcutaneous ancrod in prevention of deep-vein thrombosis after operation for fractured neck of femur. Lancet 2(8092 Pt 1): 698-700, 1978